公开(公告)号：US09844930B2

公开(公告)日：2017-12-19

申请号：US14533201

申请日：2014-11-05

申请人： Xerox Corporation

发明人： Linn C. Hoover ,  William J. Hannaway

IPC分类号： A61K9/20 ,  B33Y80/00 ,  B33Y10/00 ,  B33Y50/00 ,  B29C67/00 ,  A61K9/00 ,  A61K9/48 ,  A61J3/07 ,  B29C64/112 ,  A61D7/00

CPC分类号： B33Y80/00 ,  A61D7/00 ,  A61J3/07 ,  A61K9/0056 ,  A61K9/4825 ,  B29C64/112 ,  B33Y10/00 ,  B33Y50/00

摘要： A method for producing edible medications comprises providing a three-dimensional (3D) model of the edible medication including an internal cavity sized and shaped for receipt of a medicament therein, printing an edible media to form a portion of the 3D shell corresponding to the model for introduction of the medicament, and then printing the edible media to form the remainder of the 3D shell to completely enclose the medicament within the edible media.

公开(公告)号：US20170348329A1

公开(公告)日：2017-12-07

申请号：US15684240

申请日：2017-08-23

申请人： GLAXOSMITHKLINE LLC

发明人： Joel David GRESHOCK ,  Kurtis Earl BACHMAN ,  Samuel Charles BLACKMAN

IPC分类号： A61K31/58 ,  A61K9/20 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/48 ,  A61K47/10

CPC分类号： A61K31/58 ,  A61K9/0019 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K31/5377 ,  A61K47/10 ,  A61K2300/00

摘要： A novel combination comprising the 17 α-hydroxylase/C17,20 lyase inhibitor, (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3Kβ inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3Kβ is beneficial, e.g., cancer.

公开(公告)号：US09833485B2

公开(公告)日：2017-12-05

申请号：US14886397

申请日：2015-10-19

申请人： BEIJING KEHUITONGZHIHUI TECHNOLOGY CO., LTD.

发明人： Suying Shao ,  Jianshu Li

IPC分类号： A61K35/747 ,  A61K36/062 ,  A61K9/48 ,  A61K38/16 ,  A23K40/30 ,  A23K10/18 ,  A23K20/147 ,  A23K20/163 ,  A23K50/75 ,  A23K50/30 ,  A23K50/60

CPC分类号： A61K35/747 ,  A23K10/18 ,  A23K20/147 ,  A23K20/163 ,  A23K40/30 ,  A23K50/30 ,  A23K50/60 ,  A23K50/75 ,  A23Y2220/67 ,  A61K9/4816 ,  A61K9/4825 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K36/062 ,  A61K38/168 ,  A61K2300/00

摘要： The present invention relates to a Lactobacillus plantarum capsule and use thereof, and belongs to the technical field of microbe feed additives. The Lactobacillus plantarum capsule consists of a wall material, Lactobacillus plantarum, a cryoprotectant, stachyose, and Morchella esculenta zymolytic powders; wherein the wall material is composed of zymolytic soybean protein isolate, chitosan, xanthan gum, carrageenin, glycerin and trehalose, and when formulated into a mixed solution, the above substances have concentrations of 7 to 10% zymolytic soybean protein isolate, 1 to 2% chitosan, 1 to 3% xanthan gum, 0.1 to 0.5% carrageenin, 0.3 to 1% glycerin, and 0.5 to 2% trehalose. The Lactobacillus plantarum capsule of the present invention enhances resistance of the capsule to gastric acid, has very good enteric solubility, besides, it can effectively inhibit the growth of pathogenic germs to improve immunity, decrease incidence of diseases in livestock and poultry, and improve the breeding quality and benefit.

公开(公告)号：US20170334921A1

公开(公告)日：2017-11-23

申请号：US15670614

申请日：2017-08-07

申请人： Pharmacyclics LLC

发明人： Norbert Purro ,  Mark Stephen Smyth ,  Erick Goldman ,  David D. Wirth

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  A61J1/035 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/519 ,  A61K45/06 ,  B65D75/36 ,  C07B2200/13 ,  A61K2300/00

摘要： Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：US20170333289A1

公开(公告)日：2017-11-23

申请号：US15673789

申请日：2017-08-10

申请人： Barlean's Organic Oils, LLC

发明人： John PUCKETT

IPC分类号： A61J3/07 ,  A61K31/00 ,  A61K9/48 ,  A61K31/202 ,  A61K31/201

CPC分类号： A61J3/07 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/4833 ,  A61K31/00 ,  A61K31/201 ,  A61K31/202 ,  B29C43/08 ,  B29C43/085 ,  B29C2043/3678 ,  B30B11/165

摘要： Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.

公开(公告)号：US09820946B2

公开(公告)日：2017-11-21

申请号：US14524512

申请日：2014-10-27

申请人： Allergan Pharmaceuticals International Limited

发明人： Brendan Muldoon ,  Ryan Gerald Loughlin ,  Gerarde Sweeney ,  Emma Karen Boyd

IPC分类号： A61K9/48 ,  A61K9/66 ,  A61K31/565 ,  A61K9/00 ,  A61K47/10 ,  A61K47/22 ,  A61K9/06 ,  A61K47/36

CPC分类号： A61K9/4825 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/4866 ,  A61K31/565 ,  A61K47/10 ,  A61K47/22 ,  A61K47/36

摘要： A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.

公开(公告)号：US09816046B2

公开(公告)日：2017-11-14

申请号：US15589572

申请日：2017-05-08

申请人： AKER BIOMARINE ANTARCTIC AS

发明人： Inge Bruheim ,  Snorre Tilseth ,  Daniele Mancinelli

IPC分类号： C11B3/00 ,  A61K31/202

CPC分类号： A61K35/612 ,  A23L33/115 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/48 ,  A61K9/4825 ,  A61K9/4858 ,  A61K31/122 ,  A61K31/20 ,  A61K31/202 ,  A61K31/215 ,  A61K31/23 ,  A61K31/235 ,  A61K31/575 ,  A61K31/683 ,  A61K31/685 ,  A61K45/06 ,  C11B3/006 ,  A61K2300/00

摘要： This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

公开(公告)号：US20170319586A1

公开(公告)日：2017-11-09

申请号：US15146874

申请日：2016-05-04

申请人： Companion Supplements, LLC

发明人： Julio César Villamil Torres ,  Camilo Rey Ferro

IPC分类号： A61K31/519 ,  A61K31/714 ,  A61K31/675 ,  A61K31/525 ,  A61K31/198 ,  A61K9/48 ,  A61K36/28 ,  A61K9/00

CPC分类号： A61K31/519 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4833 ,  A61K9/4866 ,  A61K31/198 ,  A61K31/525 ,  A61K31/675 ,  A61K31/714 ,  A61K36/28 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions containing a combination of reduced forms of folate, liver protectors, vitamins, and essential or non-essential amino acids, useful in preventing the adverse effects associated with prolonged use of dihydrofolate reductase inhibitors.

公开(公告)号：US09808438B2

公开(公告)日：2017-11-07

申请号：US14959750

申请日：2015-12-04

申请人： ENZYCHEM LIFESCIENCES CORPORATION

发明人： Ki-Young Sohn

IPC分类号： A61K31/231 ,  A61K9/00 ,  A61K9/48 ,  A61K45/06 ,  A61N5/06 ,  A61N5/067

CPC分类号： A61K31/231 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4858 ,  A61K45/06 ,  A61N5/0603 ,  A61N2005/0606 ,  A61N2005/0609 ,  A61N2005/067

摘要： The invention provides a pharmaceutical composition for preventing or treating mucositis, for example oral mucositis (e.g., oral ulceration) and gastrointestinal mucositis, comprising a monoacetyldiacylglycerol compound, especially PLAG, and a method of preventing or treating mucositis using the same.

公开(公告)号：US09782374B2

公开(公告)日：2017-10-10

申请号：US15404368

申请日：2017-01-12

申请人： PATHEON SOFTGELS INC

发明人： Yunhua Hu ,  Martin Piest ,  Qi Fang ,  Henricus van Duijnhoven

IPC分类号： A61K31/196 ,  A61K31/202 ,  A61K35/60 ,  A61K9/48

CPC分类号： A61K31/196 ,  A23L29/284 ,  A23L33/12 ,  A23P10/30 ,  A61K9/4816 ,  A61K9/4825 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/202 ,  A61K35/60

摘要： Described herein are soft capsules and enteric soft capsules comprising cationic Type A gelatin and acid insoluble enteric polymers. In particular, the compositions and methods for manufacturing all-natural enteric soft capsules comprising Type A gelatin and matrix fills are described. In one embodiment, the enteric soft capsules comprise active ingredients such as non-steroidal anti-inflammatory drugs (NSAIDs). In another embodiment, the enteric soft capsule comprises matrix fills of omega-3 fatty acids.